Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Recombinant DNA

Recombinant DNA

Recombinant DNA

Recombinant DNA

Composition of Blood Plasma

Composition of Blood Plasma

Blood plasma is a fluid that contains approximately 92% water and 8% solutes. The solutes include various types of proteins, which constitute about 7% of the total solutes in the plasma. The high-molecular-weight proteins—albumins, globulins, and fibrinogen—are essential to plasma function. Albumins, making up about 60% of the plasma proteins, maintain the osmotic balance within blood vessels by preventing excessive water leakage. Additionally, albumins serve as carrier proteins, binding to...

Drug Distribution: Plasma Protein Binding

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...

Production of Pharmaceuticals

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

Conservative Site-specific Recombination and Phase Variation

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Delayed post-traumatic alopecia of the dorso-lumbar area following a road accident in a cat without pelvic fracture.

The Journal of small animal practice·2024

Same author

Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2021

Same author

Principles of haemophilia care: The Asia-Pacific perspective.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Same author

International Forum on GMP-grade human platelet lysate for cell propagation: summary.

Vox sanguinis·2017

Same author

International Forum on GMP-grade human platelet lysate for cell propagation.

Vox sanguinis·2017

Same author

Global Forum of the World Federation of Hemophilia, September 26-27, 2005, Montreal, Quebec, Canada.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2017

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System

Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System

Published on: July 17, 2021

Recombinant plasma proteins.

¹Human Protein Process Sciences, Lille, France. tburnou@attglobal.net

|December 24, 2010

Summary

This summary is machine-generated.

Recombinant DNA technology offers a promising alternative to plasma fractionation for producing therapeutic proteins, addressing limitations and enabling new treatments for immunological and bleeding disorders.

More Related Videos

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Published on: April 9, 2013

Related Experiment Videos

Last Updated: Jun 5, 2026

Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System

Production of Recombinant PRMT Proteins using the Baculovirus Expression Vector System

Published on: July 17, 2021

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP

Published on: April 9, 2013

Area of Science:

Biotechnology
Protein Therapeutics
Immunology

Background:

Plasma fractionation has historically supplied essential therapeutic proteins like coagulation factors and immunoglobulins.
Recombinant technologies in mammalian cell cultures have enabled production of complex glycoproteins, but face challenges in cost, productivity, and immunogenicity.
Advancements in cell culture and expression systems, including transgenic animals, herald a new era for recombinant plasma protein therapeutics.

Purpose of the Study:

To review the achievements and challenges of recombinant DNA technology for plasma protein production.
To compare the advantages and limitations of recombinant plasma proteins with fractionated plasma proteins.

Main Methods:

Review of existing literature on recombinant DNA technology and plasma protein production.
Analysis of advancements in mammalian cell culture and alternative expression systems.
Comparative assessment of recombinant and fractionated plasma protein products.

Main Results:

Recombinant DNA technology has progressed significantly, offering alternatives to plasma-derived therapies.
Limitations in productivity, cost, and immunogenic risks persist for some recombinant products.
Emerging technologies like transgenic animals show potential for broader and more efficient production.

Conclusions:

Recombinant DNA technology is a vital platform for plasma protein therapeutics, with ongoing innovation addressing current limitations.
Continued research into alternative cell lines and expression systems is crucial for optimizing production and expanding therapeutic options.
Understanding the comparative advantages and limitations is key to clinical application and development of novel protein therapeutics.